Plasma Protease C1-inhibitor Treatment market competition by top manufacturers/players, with Plasma Protease C1-inhibitor Treatment sales volume, Price (USD/Unit), revenue (Million USD) and market share for each manufacturer/players.
The report systematically analyzes essential details of the Global Plasma Protease C1-Inhibitor Treatment Market with the help of an in-depth and specialized analysis. Defined in a ground-up manner, the report presents a comprehensive synopsis of the market based on the factors that are predictable to have a considerable and determinate impact on the market’s developmental prospects over the prognosis period.
Key vendors in the plasma protease c1-inhibitor treatment market are engaged in expanding their product portfolio and expand their distribution networks in order to penetrate global markets. This has mandated vendors to meet the regulatory standards set by governing bodies at national and international level.
Growing investment for innovation in inhibitor drugs, promising pipeline drugs and novel therapies, and increasing awareness for hereditary angioedema (HAE) are primarily driving the plasma protease C1-inhibitor market through 2022.
One of the key drivers of the plasma protease C1-inhibitor treatment market is the increasing usage of plasma protease C1-inhibitor treatment drugs due to the increasing incidence of acute cases of hereditary angioedema (HAE) and prophylaxis. The emergence of C1-inhibitor is considered to be a major breakthrough among several drugs introduced in the plasma protease C1-inhibitor treatment market.
Berinert is a C1-esterase inhibitor for acute HAE that received approval from the European Union in 2011. Haegarda, which is derived from C1-esterase inhibitor is approved in the U.S for routine prophylaxis as a preventive measure against HAE attacks in adolescents and adults.
The increasing prevalence of diseases in children is leading to the implementation of awareness programs by various governments across the globe. Furthermore, the emergence, development and usage of hepatitis B vaccine and other such significant advancements in vaccinology should augment business growth in the years to come.
Increasing practice of administering prophylactic treatment process for HAE patient, demand for a new route of administration of C1-inhibitor drugs, rising demand for administering drugs subcutaneously among HAE patients are some other growth drivers of the plasma protease C1-inhibitor treatment market. The C1-inhibitor segment held the leading market share in 2016 as these drugs are widely used for the treatment of acute HAE and prophylaxis.
The segment of Selective Bradykining B2 Receptor is anticipated to display the leading growth rate over the forecast period. This is mainly because of expanding R&D activities that key players are engaged in for the development of new C1-inhibitor deficiency drugs that can be administered subcutaneously.
Increasing approval of Kallikrein drugs and positive results obtained for pre-clinical treatment of HAE cases are likely to augment the growth rate of this segment moderately over the forecast period.
The report provides a brief 2017-2022 timeline for each segment of the Global Plasma Protease C1-Inhibitor Treatment Market. Production figures, revenue figures, and pricing trends of each segment are provided in the report, making it a comprehensive repository on the global market.
Further the report provides 2017-2025 forecasts based on a solid analysis of the historical trajectory exhibited by each segment of the global market.
Global Plasma Protease C1-inhibitor Treatment market competition by top manufacturers/players, with Plasma Protease C1-inhibitor Treatment sales volume, Price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
- Shire plc
- CSL Limited
- Pharming Group N.V.
On the basis of product, this report displays the production, revenue, price, and market share and growth rate of each type, primarily split into
by Drug Class
- Kallikrein Inhibitor (Kalbitor)
- Selective Bradykinin B2 Receptor Antagonist (Firazyr)
by Dosage Type
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
- Hospital Pharmacies
- Independent Pharmacies and Outlets
Category: Market Research Publishers and RetailersCompany about: Research N Reports is a new age market research firm where we focus on providing information that can be effectively applied. Today being a consumer driven market, companies require information to deal with the complex and dynamic world of choices. Where relying on a sound board firm for your decisions becomes crucial. Research N Reports specializes in industry analysis, market forecasts and as a result getting quality reports covering all verticals, whether be it gaining perspective on ...